HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hand Sanitizers Offered In Liquor Bottles Among Emerging Concerns Under US FDA's Pandemic Rule

Executive Summary

Allowing "significant flexibility" for making OTC sanitizers has led to more than 1,500 additional manufacturers registered with FDA to produce hand sanitizer. But the agency says it "is addressing safety concerns related to products being sold that are not in line with the FDA's policy and others being marketed with unproven claims."

You may also be interested in...



OTC Sanitizer Contaminations Drop In US As Auxiliary Manufacturers Stop Production

"Fewer people are manufacturing the products ... That seems to be a sort of a natural reaction to I think the decreased consumer demand," says Donald Ashley, compliance chief in FDA’s drug center.

US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

First, Methanol Plagued OTC Sanitizers, Now It's Valisure: Recommends Recalls Due To Benzene

FDA should recall dozens of hand sanitizers found to contain benzene, a known human carcinogen, says Valisure, the compounding pharmacy that raised initial alarm about ranitidine in OTC heartburn drugs, leading eventually to withdrawals of the products.

Related Content

Topics

UsernamePublicRestriction

Register

RS149959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel